Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...
The most successful drug or cell therapies are often mechanistically simple and work through a single molecule or cell type. But broadly speaking, when we consider more complex diseases—heart disease, ...
SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that it is presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation which is now accessible. This year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback